Business
Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports Second Quarter 2021 F...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n VICTORIA, BC\n \n ,\n \n Aug. 13, 2021\n \n /CNW/ - Eupraxia Pharmaceuticals Inc.\n \n \n (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or \"IFRS\") and operational highlights for the second quarter ended\n \n June 30, 2021\n \n . All amounts are expressed in Canadian dollars unless otherwise noted.\n \n \n \n \n Selected Operational and Financial Highlights\n \n \n \n \n \n Subsequent to quarter end, received authorization of its Clinical Trial Application (\"CTA\") by the Danish Medicines Agency (\"DKMA\"), which is required to initiate the Company's Phase 2 clinical trial for its lead candidate EP-104IAR as a potential treatment for pain from osteoarthritis (\"OA\") of the knee. The Company remains on track to see top-line results from the trial in late 2022;\n \n \n Conducted ongoing preparations for the Phase 2 trial of EP-104IAR including labelling and release of clinical supplies, site initiation visits and the Investigator Meeting;\n \n \n Announced expansion of patient enrollment in the Phase 2 clinical trial of EP-104IAR from 220 to 300 patients;\n \n \n Built on EP-104IAR's intellectual property portfolio with a granted Canadian patent for composition and method of use. This patent is in addition to previously granted patents in\n \n the United States\n \n , European Union,\n \n China\n \n ,\n \n Japan\n \n ,\n \n Mexico\n \n and other key jurisdictions;\n \n \n Announced the appointment of industry veteran\n \n Bruce Cousins\n \n as President and CFO;\n \n \n Entered into an agreement with contract research organization Nordic Biosciences Clinical Development A/S (\"NBCD\") to conduct Eupraxia's EP-104IAR Phase 2 clinical trial ...